News und Analysen
Gilead Sciences: Remdesivir ist leider kein Allheilmittel
Gilead Sciences (WKN: 885823) ist, langfristig betrachtet, eine der größten Erfolgsgeschichten im Biotechsektor. So gelang es dem, zwischenzeitlich zu einem Konzern herangewachsenen, Unternehmen
Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, May 15, 2020 at 10:00 a.m. EDT. The purpose
Humana, Papa and Uber Health Join Industry Leaders to Remind Public They’re “Far from Alone” in Combatting Loneliness and Social Isolation
Humana Inc. (NYSE: HUM), in partnership with Uber Health, Papa, Coalition to End Social Isolation and Loneliness, and the NASA-funded Translational Research Institute for Space Health (TRISH) today
Humana Jumps 17 Spots on Benchmark List of Top 50 Companies for Diversity
Humana Inc. (NYSE: HUM) rose dramatically on the DiversityInc list of Top 50 Companies for Diversity, jumping 17 spots in making the list for the third year in a row. The list honors leadership in
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development
Humana-Owned Health Care Facilities Implement New COVID-19 Prevention Standards
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that its senior-focused primary care subsidiaries Conviva Care Centers, Partners in Primary Care, and Family Physicians
New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized
Pfizer Inc. (NYSE:PFE) today announced detailed results of the first study to show the burden of both invasive and non-invasive Group B Streptococcus infections (GBS) among hospitalized adults in
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
-
Revenue of $859 million, a 2% increase compared to
Humana Foundation Commits $50M to Coronavirus Relief and Recovery Efforts
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), today announced it will deploy $50 million in immediate short-term and long-term relief and partner with national and community
Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle
Illumina, Inc. (NASDAQ: ILMN) freut sich, bekanntgeben zu dürfen, dass die Kommission der Afrikanischen Union im Namen des Africa Center for Disease Control and Prevention (CDC)
Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance
Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation
PFIZER REPORTS FIRST-QUARTER 2020 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2020, reaffirmed its 2020 financial guidance for revenues and Adjusted diluted EPS(3) and updated certain other components of
Pfizer Hosts Virtual-Only Annual Meeting of Shareholders
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent second-quarter 2020 dividend on the company’s common stock, payable June 5, 2020 to shareholders of record at the close of
Humana and the National Quality Forum Publish Population Health Paper in the New England Journal of Medicine
Physician leaders from Humana Inc. (NYSE: HUM) and the National Quality Forum (NQF) explore the impact that social, behavioral and environmental factors – such as access to healthy foods, safe
Agilent Receives FDA Approval for PD-L1 Companion Diagnostic on Dako Omnis
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
Agilent Signs Sponsorship Agreement with My Green Lab
Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using
Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance.
Subject to quarter-end closing adjustments, the Company
Agilent Technologies Provides Update on COVID-19 Impact; Sets Second-Quarter Earnings Call for May 21
Agilent Technologies, Inc. (NYSE: A) today announced that due to the expanded and evolving nature of the COVID-19 pandemic and resulting effects on customer operations, it is withdrawing its
Pfizer Advances Battle Against COVID-19 on Multiple Fronts
Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been collaborating across
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine
Portfoliocheck: Mit United Health spielt Andreas Halvorsen die Gesundheitskarte
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment